Abstract: The claimed invention relates to treatment of virus-related respiratory distress, particularly methods for treating such distress by administering a complement inhibitor. The types of virus-related respiratory distress that can be treated according to the invention include acute respiratory distress syndrome and related phenomena, and can be linked to infection by a coronavirus such as SARS-CoV-2. The invention includes administering complement inhibitor, which can be recombinant or purified C1 inhibitor, and administering complement inhibitor in combination with other therapeutics.

Abstract: The claimed invention relates to treatment of virus-related respiratory distress, particularly methods for treating such distress by administering a complement inhibitor. The types of virus-related respiratory distress that can be treated according to the invention include acute respiratory distress syndrome and related phenomena, and can be linked to infection by a coronavirus such as SARS-CoV-2. The invention includes administering complement inhibitor, which can be recombinant or purified Cl inhibitor, and administering complement inhibitor in combination with other therapeutics.

Abstract: A pharmaceutical composition of recombinant human fibrinogen having a half-life of less than 12 hours and a pharmaceutically acceptable carrier or diluent. The pharmaceutical composition may also contain factor VIIa, factor VIII, von Willebrand's factor, or Desmopressin. The pharmaceutical composition may also contain divalent metal cations. The recombinant human fibrinogen may contain sialic acid.

Abstract: The invention provides low-half life fibrinogen as a result of recombinant expression or enzymatic and chemical removal. The low-half life fibrinogen is useful in treating or effecting prophylaxis of bleeding particularly in situations of an acute nature in which a high initial dose and rapid decline to normal or below normal levels is desirable.

Abstract: A fibrinogen with reduced half-life and low sialic acid content as a result of recombinant expression or enzymatic and chemical removal. The fibrinogen is useful in treating or effecting prophylaxis of bleeding particularly in situations of an acute nature in which a high initial dose and rapid decline to normal or below normal levels is desirable.

Abstract: The invention provides low-half life fibrinogen with reduced sialyation as a result of recombinant expression or enzymatic and chemical removal. The low-half life fibrinogen is useful in treating or effecting prophylaxis of bleeding particularly in situations of an acute nature in which a high initial dose and rapid decline to normal or below normal levels is desirable.

Abstract: The invention provides low-half life fibrinogen as a result of recombinant expression or enzymatic and chemical removal. The low-half life fibrinogen is useful in treating or effecting prophylaxis of bleeding particularly in situations of an acute nature in which a high initial dose and rapid decline to normal or below normal levels is desirable.

Abstract: The invention provides low-half life fibrinogen as a result of recombinant expression or enzymatic and chemical removal. The low-half life fibrinogen is useful in treating or effecting prophylaxis of bleeding particularly in situations of an acute nature in which a high initial dose and rapid decline to normal or below normal levels is desirable.